Restoring the Frontline: Key Takeaways from the 2025 VA/DOD Sleep Disorder Guidelines

1. The High Stakes of Sleep in the Military and Veteran Community

Sleep is not a luxury; it is a fundamental requirement for military readiness and long-term Veteran health. Data from the RAND Corporation reveals a sobering reality: 48.6% of military personnel experience poor sleep quality, with some cohorts reporting rates as high as 69%. The consequences of this epidemic—impaired cognitive function, increased cardiovascular risk, and heightened suicide risk—demand a rigorous, evidence-based response.

The 2025 VA/DOD Clinical Practice Guideline (CPG) provides the essential framework for this response. This document represents a clinical pivot toward patient-centered care, designed to improve quality of life (QoL) and systematically minimize preventable morbidity. As practitioners, our mission is to move beyond managing symptoms and toward restoring the biological readiness of our frontline.

2. Chronic Insomnia Disorder: Moving Beyond the "Quick Fix"

The 2025 guidelines emphasize that chronic insomnia is a distinct clinical diagnosis requiring a targeted intervention strategy. Per the ICSD-3-TR criteria, Chronic Insomnia Disorder is defined by difficulties initiating or maintaining sleep occurring at least three times per week for a duration of at least three months, resulting in significant daytime impairment.

The Treatment Hierarchy

The guidelines issue a clear mandate: behavioral interventions are the first line of defense.

• Cognitive Behavioral Therapy for Insomnia (CBT-I) – "Strong For" Recommendation: This is the gold standard. Unlike pharmacotherapy, which may show similar efficacy in the short term (2-4 weeks), CBT-I provides superior long-term outcomes and sustained remission.
• Brief Behavioral Treatment for Insomnia (BBT-I) – "Weak For" Recommendation: While effective, the recommendation is weaker because the evidence base is smaller and focused primarily on older adults. It remains a viable alternative when the full CBT-I protocol is unavailable.

Core Components of Behavioral Intervention

Successful treatment relies on a multi-pronged approach (Sidebar 3):

• Sleep Restriction: Limiting time in bed to actual sleep duration to increase homeostatic sleep drive.
• Stimulus Control: Re-associating the bed with sleep rather than wakeful frustration.
• Arousal Reduction: Utilizing relaxation techniques (e.g., diaphragmatic breathing) to lower physiological tension.
• Cognitive Restructuring: Specifically within CBT-I, this addresses the "racing mind" and inaccurate beliefs about sleep that fuel the insomnia cycle.

3. Navigating the Sleep Apnea Journey: From Diagnosis to Therapy

Obstructive Sleep Apnea (OSA) represents a significant force-protection risk. The 2025 guidelines offer a "Strong For" recommendation for objective testing (PSG or HSAT) over clinical suspicion alone. While the In-Laboratory Polysomnogram (PSG) remains the gold standard, the Home Sleep Apnea Test (HSAT) is a suggested alternative for uncomplicated patients with a high pre-test probability of moderate-to-severe OSA.

Comparison of First-Line Treatments (AHI 5 to <30)

For mild-to-moderate OSA, the choice between Positive Airway Pressure (PAP) and Mandibular Advancement Devices (MAD) should be guided by patient preference and operational environment.

Treatment	Description	Cautions & Criteria
Positive Airway Pressure (PAP)	Pneumatic splinting of the airway via a mask and machine.	First-line for severe OSA (AHI >30). Preferred for patients with significant comorbidities.
Mandibular Advancement Device (MAD)	Custom dental appliance that stabilizes the mandible forward.	A "force multiplier" for active-duty personnel in austere environments lacking electricity. Contraindicated for unstable dentition.

Clinical Note on Supplemental Therapy: For patients with overweight or obesity, weight management is a vital adjunct (Recommendation 20). Clinicians should cross-reference the VA/DOD CPG on the Management of Overweight and Obesity for integrated care. Additionally, Positional Therapy (Recommendation 21) is now suggested for patients whose apnea is predominantly supine-related.

4. Pharmacotherapy: What’s In and What’s Out

When behavioral interventions are insufficient, pharmacotherapy must be applied with surgical precision and clear exit strategies.

Suggested Agents (Recommendation 9)

For short-term management, the following agents are suggested:

• Dual Orexin Receptor Antagonists (DORAs): Daridorexant, Lemborexant, Suvorexant.
• Non-Benzodiazepine Receptor Agonists ("Z-drugs"): Eszopiclone, Zaleplon, Zolpidem.
• Histamine Receptor Antagonists: Low-dose Doxepin.

Agents to Avoid (Recommendation 10)

The 2025 guidelines recommend against the following for chronic insomnia:

• Antipsychotics (e.g., Quetiapine)
• Benzodiazepines
• Diphenhydramine
• Trazodone

Consultant’s Note on Trazodone: Despite its common off-label use within the VA, current evidence indicates that the potential for harm—including grogginess, priapism, and suicidal ideation—outweighs the clinical benefits for chronic insomnia.

⚠️ WARNING: FDA SAFETY ANNOUNCEMENT All patients prescribed "Z-drugs" (Eszopiclone, Zaleplon, Zolpidem) must be counseled on the risk of complex sleep behaviors. These activities (sleep-driving, sleep-walking) can occur after a single dose and have resulted in serious injury or death.

5. Complementary Approaches: Fact vs. Fiction

Patients frequently seek "natural" alternatives, but the evidence for most is remarkably thin.

• Strong Against: Kava is strictly recommended against due to the documented risk of severe liver damage.
• Weak Against: The following lack sufficient efficacy for chronic insomnia: Cannabis/Derivatives, Melatonin, Valerian, Chamomile, Passionflower, and Saffron.
• Neither For Nor Against: Magnesium and Aerobic Exercise. While essential for general health, they are not supported by evidence as primary treatments for chronic insomnia.

6. The Power of Shared Decision-Making

Effective sleep medicine in the military context requires Shared Decision-Making (SDM). A one-size-fits-all approach fails when confronted with the realities of the field or the complexities of trauma.

Patient-Centered Care means treatment plans must be calibrated for:

• Co-occurring Conditions: Adapting protocols for those with PTSD or TBI.
• Operational Demands: Selecting MAD for a special operator in a remote setting where PAP is logistically impossible.
• Personal Values: Respecting the patient's preference for behavioral change over long-term dependency on medication.

7. Conclusion: Actionable Steps for Better Sleep

The Bottom Line

1. Prioritize Behavior First: Refer for CBT-I as the primary intervention; its long-term temporal advantage is unmatched.
2. Demand Objective Data: Diagnose OSA via PSG or HSAT; clinical "gut feeling" is insufficient for a condition with such high cardiovascular risk.
3. Evaluate for Surgery or MAD: For mild-to-moderate OSA, Mandibular Advancement Devices are validated first-line alternatives, especially in austere environments.
4. Audit the Med List: Deprescribe benzodiazepines and antipsychotics for sleep; use suggested agents like DORAs only when necessary.
5. Address the Whole Patient: Integrate weight management and positional therapy as supplemental treatments for OSA.

Call to Action

Engagement starts with the right questions. Providers should utilize the Athens Insomnia Scale (AIS) or Insomnia Severity Index (ISI) for insomnia, and the STOP questionnaire for OSA risk. The STOP tool is recommended for its simplicity and ease of administration in high-volume clinics. Sleep health is a pillar of mission success—let us treat it as such.